The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Canadian Journal of Physiology and Pharmacology

• Publication date

  2007-07-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1139/Y07-036PMID 17632588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.

  2008cited by this paper
• Impaired energetics in heart failure - a new therapeutic target.

  2008cited by this paper
• Impact of lactate in the perfusate on function and metabolic parameters of isolated working rat heart

  2007cited by this paper
• Trimetazidine improved Ca2+ handling in isoprenalinemediated myocardial injury of rats

  2006cited by this paper
• The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.

  2006cited by this paper
• Fatty acid metabolism is enhanced in type 2 diabetic hearts.

  2005cited by this paper
• Acute effects of trimetazidine evaluated by exercise testing

  2004cited by this paper
• Effects of trimetazidine on myocardial preconditioning in anesthetized rats.

  2004cited by this paper
• Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

  2003cited by this paper
• Prevention of Heart Failure in Rats by Trimetazidine Treatment: A Consequence of Accelerated Phospholipid Turnover?

  2003cited by this paper
• Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase

  2003cited by this paper
• Cardiovascular Diabetology BioMed Central Original Investigation

  2003cited by this paper
• Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

  2003cited by this paper
• Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice

  2002cited by this paper
• Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

  2002cited by this paper
• The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

  2002cited by this paper
• Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms

  2002cited by this paper
• Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies.

  2001cited by this paper
• Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy.

  2001cited by this paper
• Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine.

  2001cited by this paper
• Influence of Trimetazidine on the synthesis of complex lipids in the heart and other target organs

  2001cited by this paper
• Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model.

  2001cited by this paper
• Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand.

  2001cited by this paper
• PPAR signaling in the control of cardiac energy metabolism.

  2000cited by this paper
• The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

  2000influential reference
• The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1.

  1999cited by this paper
• Proposed Antiischemic Effects of Trimetazidine in Coronary Diabetic Patients. A Substudy from TRIMPOL-1

  1999cited by this paper
• Is the cytoprotective effect of trimetazidine associated with lipid metabolism?

  1998cited by this paper
• Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.

  1998cited by this paper
• Regulation of energy substrate metabolism in the diabetic heart.

  1997cited by this paper
• Trimetazidine increases phosppholipid turnover in ventricular myocyte

  1997cited by this paper
• Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6.

  1997cited by this paper
• Combination treatment with trimetazidine and diltiazem in stable angina pectoris

  1997cited by this paper
• Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism.

  1996cited by this paper
• Cardiac efficiency is improved after ischemia by altering both the source and fate of protons.

  1996cited by this paper
• Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators.

  1995cited by this paper
• Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.

  1994cited by this paper
• Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine

  1993cited by this paper
• Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine.

  1992cited by this paper
• Combination of trimetazidine with nifedipine in effort angina

  1990cited by this paper
• Antiischemic effect of trimetazidine: Enzymatic and electric response in a model of in-vitro myocardial ischemia

  1990cited by this paper
• Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study

  1990cited by this paper
• Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats.

  1989cited by this paper
• CARDIOPROTECTIVE EFFECT OF TRIMETAZIDINE AND NIFEDIPINE IN GUINEA-PIG HEARTS SUBJECTED TO ISCHEMIA

  1989cited by this paper
• Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischaemia.

  1989cited by this paper
• Fatty Acid Metabolism

  1988cited by this paper
• [The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study].

  1986cited by this paper

• The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy

  2023cites this paper
• The Effects of Low-dose Empagli ozin on Cardiac Function in a Rat Model of Streptozotocin-induced Diabetes

  2021cites this paper
• The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity

  2021cites this paper
• Structural and Functional Remodeling of Mitochondria in Cardiac Diseases

  2021cites this paper
• Trimetazidine Increases Plasma MicroRNA-24 and MicroRNA-126 Levels and Improves Dyslipidemia, Inflammation and Hypotension in Diabetic Rats

  2020cites this paper
• Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress.

  2019cites this paper
• The Beneficial Effects of Trimetazidine on Reperfusion–Induced Arrhythmia in Diabetic Rats

  2018cites this paper
• An evaluation of trimetazidine as a therapeutic intervention in a newly established ex vivo mouse model of acute heart failure

  2016cites this paper
• PPARβ/δ and lipid metabolism in the heart.

  2016cites this paper
• rofiling of human myotubes reveals an intrinsic proteomic ignature associated with type 2 diabetes

  2014cites this paper
• Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy

  2014influential citation
• Substrate Metabolism in the Diabetic Heart

  2014cites this paper
• Profiling of human myotubes reveals an intrinsic proteomic signature associated with type 2 diabetes

  2014cites this paper
• Atherosclerotic Coronary Artery Disease

  2013cites this paper
• Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats.

  2013cites this paper
• Bibliography--editors' selection of current world literature.

  2008cites this paper
• Trimetazidina como aditivo em solução cardioplégica sem pré-tratamento não traz proteção adicional ao miocárdio isquêmico: estudo em modelo suíno de coração isolado Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart mo

  2008cites this paper
• Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.

  2008cites this paper
• Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart model.

  2008cites this paper
• Impaired energetics in heart failure - a new therapeutic target.

  2008cites this paper